Morphine Sulfate
NDC Package 58177-340-11
Package Information
Morphine Sulfate is extended-release tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.Morphine sulfate extended-release tablets are NOT intended for use as a prn analgesic.Morphine sulfate extended-release 100 mg and 200 mg tablet strengths are high dose, controlled-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only.Morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established.Morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time.Morphine sulfate extended-release tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Marketed by Ethex Corporation, this product is identified by NDC 58177-340 and is authorized under FDA application ANDA077855.
Identification & Billing
- RxCUI: 891874 - morphine sulfate 100 MG Extended Release Oral Tablet
- RxCUI: 891874 - MS 100 MG Extended Release Oral Tablet
- RxCUI: 891881 - morphine sulfate 15 MG Extended Release Oral Tablet
- RxCUI: 891881 - MS 15 MG Extended Release Oral Tablet
- RxCUI: 891888 - morphine sulfate 30 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 58177 - Ethex Corporation
- 58177-340 - Morphine Sulfate
- 58177-340-11 - 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK
- 58177-340 - Morphine Sulfate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (58177-340). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58177-340-11 identifies a specific commercial package of 100 tablet, film coated, extended release in 1 blister pack of Morphine Sulfate, labeled by Ethex Corporation. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Ethex Corporation on January 01, 2009. The current certification is valid through December 31, 2017.
How is this Ethex Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58177034011. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.